Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.

Original title: “BrainChild hauls in $116M to make cell therapies for childhood brain cancers”

Elevara Medicines has appointed Dr Mai-Britt Zocca as CEO

Original title: “Dr Mai-Britt Zocca”

Belgium and the Netherlands have built some of Europe's strongest life sciences ecosystems, powered by leading research institutions and a growing pool of experienced biotech talent. While early-stage funding remains scarce and investment is often fragmented across regions, investors see national biotech initiatives and broader EU support as catalysts for future growth.

Original title: “Can Benelux turn scientific strength into larger biotech scale?”

Foundation models will change the way we study the natural, applied and clinical sciences, but only under certain conditions, and not in the way that some AI leaders claim.

Original title: “AI will only revolutionize drug discovery and development if we play to its strengths”

After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.

Original title: “Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’”

While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's disease.

Original title: “Reeling from past failures, Parkinson's pipeline enters 'era of diversification'”

Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

Original title: “This week in charts: China deals, stock flatlines and Lilly’s M&A spree”

Seven of the 10 companies participating in the fall cohorts of MassBio and SCbio’s Drive program are based in the United States, including four in Massachusetts.

Original title: “10 life sciences startups selected for accelerator program”

The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of the pharma.

Original title: “Pfizer punts Seagen ADC, further muddying value of the $43B buyout”

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

Original title: “GSK wagers up to $1.3B on a different kind of cancer drug”

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.

Original title: “Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study”

TScan Therapeutics is looking for strategic partnerships for its heme and autoimmune programs while working to advance two in vivo T cell therapy candidates into investigational new drug–enabling studies.

Original title: “TScan cuts 75% of workforce while shifting focus to solid tumor program”

A new program from ARPA-H has devoted funding to make individualized RNA-based genetic medicine more efficient to produce and improve accessibility.

Original title: “US to grant up to $125M for personalized RNA manufacturing innovation”